PCAR-019 (Anke Biotechnology)

靶向CD19自体嵌合抗原受体T细胞（安科生物）

Report date: 2024/09/06 20:00:43

Base Information

Drug NamePCAR-019 (Anke Biotechnology)
Drug Alias Name靶向CD19自体嵌合抗原受体T细胞输注CD19-CAR (Anke Biotechnology)靶向CD19自体嵌合抗原受体T细胞（博安吉安科）
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesAnhui Anke Biotechnology (Group) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesPersongen Anke Cell Technology Co Ltd
Inactive CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
Active IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[5] 

Other Information

ATC CodeN/A
Related LinksN/A